Mount Pleasant, MI, 2 August, 2007: Dendritic Nanotechnologies Inc (DNT), a subsidiary of Starpharma (ASX: SPL, OTCQX: SPHRY) will use its proprietary technology to purify water following the award of a contract with the US Department of Defense (DoD).

The US$1.3m development contract with the DoD’s Strategic Environmental Research and Development Program (SERDP) was awarded to DNT and the Central Michigan University Research Corporation to develop water remediation technology using new Priostar™ dendrimer-based nanotechnology.

The initial water remediation target is perchlorate, a chemical that has contaminated the groundwater in some US regions.  The Center for Disease Control & Prevention (CDC) has reported that low levels of perchlorate are widespread throughout the U.S, and 27 DoD facilities have been identified with perchlorate contamination.  Perchlorate contamination potentially affects the health of millions of women. It can interfere with iodide uptake by the thyroid gland.

Traditional methods of remediation such as reverse osmosis and filtration have been ineffective in recovering perchlorate from contaminated water.  As perchlorate contamination has been associated with the discharge of wastewater from military installations, the DOD is in critical need of more cost effective and environmentally acceptable technologies capable of removing perchlorate from drinking water to below 2 ppb.
 
Successful completion of this project, which was sponsored by U.S. Senator Carl Levin and Congressman David Camp, will provide DoD with a new generation of cost effective, environmentally acceptable water remediation system.  

This technology will also open up opportunities into the public sector.  The multi-purpose Priostar technology will also be effective in removing and recovering metals such as cadmium, chromium, copper, manganese, molybdenum, lead, nickel, silver, zinc and other contaminants such as arsenic, and mercury which are found in waters worldwide.

An economical and versatile solution for a water remediation and recovery system that is cost effective, recovers precious metals for recycling, and releases water that exceeds clean water standards back into the environment will be highly desired worldwide.

About Dendritic Nanotechnologies Inc. (DNT): Starpharma’s wholly owned U.S. based operating subsidiary – Dendritic Nanotechnologies, Inc. located in Mount Pleasant, Michigan - provides innovative dendrimer technologies and commercialization services with its new proprietary Priostar™ dendrimer technologies. Priostar™ dendrimers are the newest generation of dendrimers and were engineered to be commercially viable (reduced manufacturing complexity and costs). The company has patents pending on its Priostar™ family of dendrimers. PrioFect, Priostar and STARBURST® are trademarks of Dendritic Nanotechnologies, Inc. All other trademarks mentioned herein are held by their respective owners.

About Starpharma: Starpharma Holdings Limited (ASX:SPL, OTCQX:SPHRY) is a world leader in the development of dendrimer nanotechnology for pharmaceutical, life-science and other applications. SPL is principally composed of two operating companies, Starpharma Pty Ltd in Melbourne, Australia and Dendritic Nanotechnologies, Inc in Michigan, USA.

American Depositary Receipts (ADRs): Starpharma’s ADRs trade under the code SPHRY (CUSIP number 855563102). Each Starpharma ADR is equivalent to 10 ordinary shares of Starpharma as traded on the Australian Stock Exchange. The Bank of New York is the depositary bank.

For further information:
www.starpharma.com       

Media:
Rebecca Wilson
Buchan Consulting
Tel: +61 2 9237 2800
Mob: +61 417 382 391
rwilson@bcg.com.au
  
Starpharma:
Dr Jackie Fairley
Chief Executive Officer Starpharma Holdings Ltd
+61 3 8532 2700
jackie.fairley@starpharma.com 
 
Dr Robert Berry
President,
DNT
Tel: 989.774.1799
berry@dnanotech.com
    
Ben Rogers
Company Secretary
Starpharma Holdings Ltd
+61 3 8532 2702
ben.rogers@starpharma.com
    

Online ordering of STARBURST® dendrimers now available.
06-25-2008

First commercial product launch of Starpharma’s DNT Priostar® Dendrimers
- EMD Chemicals Inc. launches DNA Transfection Reagent Kit -
04-22-2008

Starpharma signs agreement with Unilever
04-07-2008

New Lower Pricing on STARBURST® PAMAM Dendrimers
02-26-2008

Oncologix Tech, Inc. and Dendritic Nanotechnologies, Inc. Resolve Leaching Issues with the Oncosphere Product
08-22-2007